3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Hematologic Diseases
1
Bone Marrow Diseases
1
Interventions
Azacitidine
38
Cytarabine
22
venetoclax
19
fludarabine phosphate
18
fludarabine
18
Cyclophosphamide
18
Peripheral Blood Stem Cell Transplantation
15
Tacrolimus
14
Filgrastim
13
Decitabine
13
Mycophenolic Acid
12
Busulfan
12
Whole-Body Irradiation
11
Melphalan
11
Methotrexate
10
Cyclosporine
10
Antilymphocyte Serum
8
Stem Cell Transplantation
7
Alemtuzumab
7
decitabine and cedazuridine drug combination
6
Granulocyte Colony-Stimulating Factor
6
Clofarabine
6
AP 1903 reagent
6
Thiotepa
5
Rituximab
5
Idarubicin
5
quizartinib
4
Tretinoin
4
Sirolimus
4
Radiotherapy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Myelodysplastic Syndromes
×
Clinical Laboratory Techniques
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled